Numis Securities Ltd Reiterates Buy Rating for Allergy Therapeutics plc (AGY)
Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reiterated by analysts at Numis Securities Ltd in a research report issued to clients and investors on Monday. They presently have a GBX 37 ($0.48) price objective on the stock. Numis Securities Ltd’s target price would suggest a potential upside of 89.74% from the stock’s current price.
A number of other research analysts also recently weighed in on AGY. Panmure Gordon reiterated a “buy” rating and set a GBX 53 ($0.69) price target on shares of Allergy Therapeutics plc in a report on Friday, July 8th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 72 ($0.94) price target on shares of Allergy Therapeutics plc in a report on Friday, July 8th.
Allergy Therapeutics plc (LON:AGY) opened at 21.70 on Monday. Allergy Therapeutics plc has a one year low of GBX 17.25 and a one year high of GBX 34.82. The company’s 50-day moving average price is GBX 18.82 and its 200-day moving average price is GBX 22.15. The firm’s market cap is GBX 127.85 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/numis-securities-ltd-reiterates-buy-rating-for-allergy-therapeutics-plc-agy.html
In other news, insider Nicolas Wykeman acquired 150,000 shares of Allergy Therapeutics plc stock in a transaction that occurred on Tuesday, September 27th. The stock was purchased at an average price of GBX 18 ($0.23) per share, with a total value of £27,000 ($35,243.44). Also, insider Peter Jensen acquired 30,000 shares of Allergy Therapeutics plc stock in a transaction that occurred on Thursday, September 29th. The shares were purchased at an average cost of GBX 19 ($0.25) per share, with a total value of £5,700 ($7,440.28).
About Allergy Therapeutics plc
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.